Eli Lilly (LLY) stumbled out of the gate in 2026. The pharmaceutical giant’s shares fell roughly 4% in a single session after the U.S. Food and Drug Administration (FDA) extended its review timeline for the company’s highly anticipated oral weight-loss drug, orforglipron. The agency set a new decision date of April 10, postponing an expected late-February approval.
This delay hands rival Novo Nordisk (NVO) a clearer head start. Novo’s oral version of Wegovy gained FDA approval in December, allowing it to capture first-mover advantage in the emerging oral GLP-1 market. The setback has investors questioning: Does this regulatory hurdle undermine the thesis that 2026 could be “the Year of Eli Lilly”?
On the surface, the postponement is undoubtedly negative. Oral therapies, with their convenience (no injections, no cold storage), are seen as the key to unlocking the next wave of demand in the obesity drug market. Novo Nordisk currently holds that key alone, gaining precious months to reach patients hesitant about injectable treatments.
However, history suggests that in the weight-loss drug marathon, first-mover advantage isn’t everything. While Novo’s injectable Wegovy launched over two years before Lilly’s Zepbound, Zepbound’s sales had surpassed Wegovy’s by the third quarter of 2025. Ultimate product competitiveness hinges on a blend of efficacy, safety, tolerability, and convenience.
This is where Lilly’s confidence lies. Phase 3 trial data for orforglipron has been solid. Crucially, unlike oral Wegovy which requires patients to fast for 30 minutes after dosing, orforglipron involves no dietary restrictions, making it far easier to integrate into daily life. This distinct convenience edge could become a powerful weapon in the battle for market share.
Zooming out, orforglipron is just one new cylinder in Lilly’s powerful engine. Its core growth drivers—the injectable therapies Mounjaro and Zepbound—continue to see robust demand, generating massive cash flow. The company’s weight-loss portfolio delivered over $10 billion in revenue last quarter, growing at a double-digit clip.
Furthermore, Lilly boasts an attractive mid- and late-stage pipeline in obesity and metabolic diseases, securing long-term growth potential. The company’s strong financials and robust dividend program add further support for the stock.
Many analysts believe the market’s reaction to a roughly six-week delay may be excessive. The extension is likely a routine case of the FDA needing more time to review submitted data, not a reflection of concerns over the drug’s safety or efficacy.
For investors, Lilly’s fundamental investment case remains intact: it is a clear leader in the global weight-loss drug duopoly, with best-in-class products, strong manufacturing capacity, and deep R&D reserves. Short-term regulatory noise may have created a more attractive entry point for long-term believers.
Whether 2026 truly becomes “the Year of Eli Lilly” will ultimately depend on the execution of its oral drug launch and the sustained performance of its entire portfolio. For now, evidence suggests this pharma titan’s growth story is far from over.
